Who are DMB-I (INN: Latrepirdine)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Butylphthalide Soft Capsules, NeuroAiD, Citicoline eye drops 2%, EGb761, Edaravone Dexborneol Sequential Therapy, Riluzole (100 mg).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dmb-i-inn-latrepirdine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

DMB-I (INN: Latrepirdine) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

DMB-I (INN: Latrepirdine) (DMB-I (INN: Latrepirdine)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Neuroprotective agent. Area: Neurology.

phase 3 Neuroprotective agent NMDA receptor, mitochondrial membrane, monoamine oxidase Neurology Small molecule Live · refreshed every 30 min

Target snapshot

DMB-I (INN: Latrepirdine) (DMB-I (INN: Latrepirdine)) — Bigespas LTD. Latrepirdine is a neuroprotective agent that modulates mitochondrial function and reduces neuronal excitotoxicity through multiple pathways including NMDA receptor antagonism and monoamine oxidase inhibition.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
DMB-I (INN: Latrepirdine) TARGET	DMB-I (INN: Latrepirdine)	Bigespas LTD	phase 3	Neuroprotective agent	NMDA receptor, mitochondrial membrane, monoamine oxidase
Butylphthalide Soft Capsules	Butylphthalide Soft Capsules	Peking Union Medical College Hospital	marketed	Neuroprotective agent
NeuroAiD	NeuroAiD	CHIMES Society	marketed	Herbal neuroprotective agent
Citicoline eye drops 2%	Citicoline eye drops 2%	Omikron Italia S.r.l.	phase 3	Neuroprotective agent / Membrane repair agent	Phospholipid synthesis pathway (CDP-choline pathway)
EGb761	EGb761	Ipsen	phase 3	Herbal extract / Neuroprotective agent
Edaravone Dexborneol Sequential Therapy	Edaravone Dexborneol Sequential Therapy	Simcere Pharmaceutical Co., Ltd	phase 3	Neuroprotective agent combination
Riluzole (100 mg)	Riluzole (100 mg)	AB Science	phase 3	Glutamate antagonist / Neuroprotective agent	Glutamate release (presynaptic); voltage-gated sodium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Neuroprotective agent class)

Bigespas LTD · 1 drug in this class
Capital Medical University · 1 drug in this class
Peking Union Medical College Hospital · 1 drug in this class
Rong Hu, MD · 1 drug in this class
Sanofi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DMB-I (INN: Latrepirdine) — Competitive Intelligence Brief. https://druglandscape.com/ci/dmb-i-inn-latrepirdine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab